Excellent
Mostly Aligned
Patient Risk:
Low
Summary
The claim matches the FDA boxed warning and Section 5.1 language describing increased all-cause mortality risk in elderly patients with dementia-related psychosis treated with antipsychotic drugs, including VRAYLAR.
Category Scores
Accurate Statements
Increased mortality in elderly patients with dementia-related psychosis
BOXED WARNING: "Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death." and Section 5.1: "Antipsychotic drugs increase the all-cause risk of death in elderly patients with dementia-related psychosis."
Unsupported Statements
Contradictions
Important Omissions
Whether VRAYLAR is not approved for dementia-related psychosis (boxed warning includes this statement).
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The evaluated claim is an on-label warning statement and does not add inaccurate or additional risk beyond what is described in the label excerpt.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
The claim does not explicitly include the label’s statement that VRAYLAR is not approved for dementia-related psychosis.
Suggested Improvement
If presenting boxed warning content verbatim or more completely, include the accompanying phrase: "VRAYLAR is not approved for the treatment of patients with dementia-related psychosis."